Browsing by author "van der Graaf, Wilhelmina"
Now showing items 21-40 of 44
-
Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.
Boon, E; van der Graaf, WTA; Gelderblom, H; Tesselaar, MET; van Es, RJJ; et al. (2017-01)Background There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck.Methods All records of patients older than 16 years diagnosed with ... -
Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.
Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; et al. (2017-01)Gastrointestinal stromal tumors (GISTs) are composed of various molecular subtypes, with differing prognostic and predictive relevance. Previously, tumors lacking mutations in the KIT and PDGFRA genes have been designated ... -
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.
van der Graaf, WTA; Tielen, R; Bonenkamp, JJ; Lemmens, V; Verhoeven, RHA; et al. (2018-07)BACKGROUND:The incidence, treatment and outcome of patients with newly diagnosed gastrointestinal stromal tumour (GIST) were studied in an era known for advances in diagnosis and treatment. METHODS:Nationwide population-based ... -
Olaratumab in soft-tissue sarcomas.
van der Graaf, WTA (2016-07) -
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson, C; Ray-Coquard, I; Sleijfer, S; Litière, S; Blay, J-Y; et al. (2016-07)Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest outcome to systemic therapy, and poor overall survival. Pazopanib ... -
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger, E; Litière, S; Le Cesne, A; Mir, O; Gelderblom, H; et al. (2018-10)BACKGROUND:Almost half of patients diagnosed with soft tissue sarcoma (STS) are older than 65 years; however, the outcomes of elderly patients with metastatic disease are not well described. PATIENTS AND METHODS:An elderly ... -
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár, A; Jones, RL; Stacchiotti, S; Gelderblom, H; Guida, M; et al. (2017-01)Background Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy ... -
Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs, Z; Messiou, C; Wong, HH; Hatcher, H; Miah, A; et al. (2017-04)Desmoid tumour/aggressive fibromatosis (DT/AF) is a rare soft-tissue neoplasm that is locally aggressive but does not metastasize. There is no standard systemic treatment for symptomatic patients, although a number of ... -
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young, RJ; Litière, S; Lia, M; Hogendoorn, PCW; Fisher, C; et al. (2017-07)Background The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma ... -
Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.
Sleijfer, S; Rizzo, E; Litière, S; Mathijssen, RHJ; Judson, IR; et al. (2018-08)INTRODUCTION:As both anti-tumour effects and toxicity are thought to be dose-dependent, patients with the greatest toxicity may also have the best outcome. We assessed whether severity of doxorubicin-induced hematological ... -
Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors.
Poort, H; van der Graaf, WTA; Tielen, R; Vlenterie, M; Custers, JAE; et al. (2016-08)Context The introduction of the tyrosine kinase inhibitor (TKI) imatinib in the treatment of gastrointestinal stromal tumor (GIST) in 2000 was the start of a new era of targeted treatment. Since then, the median survival ... -
Promising novel therapeutic approaches in the management of gastrointestinal stromal tumors.
Szucs, Z; Thway, K; Fisher, C; Bulusu, R; Constantinidou, A; et al. (2017-01)Primary and secondary resistance to currently available licensed tyrosine kinase inhibitors poses a real clinical challenge in the management of advanced gastrointestinal stromal tumors. Within the frame of early phase ... -
Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.
Driessen, CML; Groenewoud, JMM; de Boer, JP; Gelderblom, H; van der Graaf, WTA; et al. (2018-04)PURPOSE:The CONDOR study showed that docetaxel/cisplatin/5-fluorouracil (TPF) followed by conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 (cis100 + RT; n = 27)) versus accelerated radiotherapy with ... -
Sarcoma: Olaratumab - really a breakthrough for soft-tissue sarcomas?
Judson, I; van der Graaf, WT (2016-09) -
Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts.
van der Graaf, WTA; Orbach, D; Judson, IR; Ferrari, A (2017-03-02)Survival outcomes for adolescent and young adult patients with soft tissue sarcomas lag behind those of children diagnosed with histologically similar tumours. To help understand these differences in outcomes, we discuss ... -
Systemic Treatment for Adults with Synovial Sarcoma.
Desar, IME; Fleuren, EDG; van der Graaf, WTA (2018-03-07)Opinion statement Synovial sarcoma (SS) is a rare, yet highly malignant, type of soft tissue sarcoma (STS), for which survival has not improved significantly during the past years. In this review, we focus on systemic ... -
Systemic treatment in adult uterine sarcomas.
Desar, IME; Ottevanger, PB; Benson, C; van der Graaf, WTA (2018-02)Uterine sarcomas (US) are rare mesenchymal tumours of the uterus and are divided mainly into uterine leiomyosarcoma (uLMS), low grade endometrial stromal sarcoma (LG-ESS), high grade endometrial stromal sarcoma (HG-ESS), ... -
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
van Erp, AEM; Hillebrandt-Roeffen, MHS; van Houdt, L; Fleuren, EDG; van der Graaf, WTA; et al. (2017-12)The receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK) has been implicated in the tumorigenesis of rhabdomyosarcoma (RMS). However, the exact role of ALK in RMS is debatable and remains to be elucidated.To ... -
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie, M; Hillebrandt-Roeffen, MHS; Schaars, EWM; Flucke, UE; Fleuren, EDG; et al. (2016-09)Background In synovial sarcomas alterations in the cyclin D1-CDK4/6-Rb axis have been described. Also, β-catenin, a cyclin D1 regulator, is often overexpressed. Additionally, studies have shown that the t(X;18) translocation ... -
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
Casali, PG; Zalcberg, J; Le Cesne, A; Reichardt, P; Blay, J-Y; et al. (2017-05)Purpose To report on the long-term results of a randomized trial comparing a standard dose (400 mg/d) versus a higher dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs). ...